Citi analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. on June 17 and set a price target of HK$37.00. The company’s shares clos...
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Giant Biogene Holding Co. Ltd. with a HK$40.19 average price target.
Based on Giant Biogene Holding Co. Ltd.’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$2.41 billion and a net profit of HK$732.75 million. In comparison, last year the company earned a revenue of HK$3 billion and had a net profit of HK$1.08 billion
In a report released on June 11, from UBS maintained a Hold rating on Giant Biogene Holding Co. Ltd., with a price target of…
Citic Securities analyst maintained a Buy rating on Super Hi International Holding Ltd. on May 23 and set a price target of…
In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of…
Bank of America Securities analyst maintained a Buy rating on CITIC Securities Co on May 28 and set a price target of HK$35.70.…
In a report released on June 25, from Citi maintained a Buy rating on Trip.com Group Ltd., with a price target of HK$499.20. The…
In a report released on June 25, from Citi maintained a Buy rating on China National Building Material Co, with a price target…
